Company profile

Henan Genuine Biotech

Privately held: no public share price

Assets

(4 total)
4Total Assets
1Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Azvudine(FNC)
Approved
HIV reverse transcriptaseSmall molecule
HIV
CL-197
Phase 2
HIV reverse transcriptaseSmall molecule
HIV
Dositinib mesylate
Phase 2
EGFRSmall molecule
Non-Small Cell Lung Cancer
GEN-725
Phase 2
Undisclosed / early pipelineSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.